Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome

Annals of Neurology

Volumn 45, Issue 4, 1999, Pages 537-541

  Matsubara, Etsuro ^a,c   Ghiso, Jorge ^b   Frangione, Blas ^b   Amari, Masakuni ^a   Tomidokoro, Yasushi ^a   Ikeda, Yoshio ^a   Harigaya, Yasuo ^a   Okamoto, Koichi ^a   Shoji, Mikio ^a  

^a GUNMA UNIVERSITY   (Japan)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LIPOPROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; HUMAN; PLASMA CLEARANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LIPID INTERACTION; SCHOOL CHILD;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS; PEPTIDE FRAGMENTS;

EID: 0032946019     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2     Document Type: Article

References (22)

1. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126-129
2. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β peptide from biological fluids. Nature 1992;359:325-327
3. Vigo-Pelfrey C, Lee D, Keim P, et al. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993;61:1965-1968
4. Ghiso J, Calero M, Matsubara E, et al. Alzheimer's soluble amyloid β is a normal component of human urine. FEBS Lett 1997;408:105-108
5. Tabaton M, Nunzi MG, Xue R, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994;200: 1598-1603
6. Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-8382
7. Teller JK, Russo C, DeBusk L, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996;2:93-95
8. Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994;205: 1164-1171
9. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J Biol Chem 1995; 270:7563-7567
10. Matsubara E, Soto C, Governale S, et al. Apolipoprotein J and Alzheimer's amyloid β solubility. Biochem J 1996;316:671-679
11. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid β peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996;271:32916-32922
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944
13. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 1994;264:1336-1340
14. Asami-Odaka A, Ishibashi Y, Kikuchi T, et al. Long amyloid β-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 1995;34:10272-10278
15. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2: 864-870
16. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 1993;90:2092-2096
17. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997;148:41-45
18. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome. Ann Neurol 1997;41:271-273
19. Zlokovic BV, Ghiso J, Mackic JB, et al. Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem Biophys Res Commun 1993;197:1034-1040
20. Maness LM, Banks WA, Podlisny MB, et al. Passage of human amyloid β protein 1-40 across the murine blood-brain barrier. Life Sci 1994;55:1643-1650
21. 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996;7:2607-2611
22. Kosaka T, Imagawa M, Seki K, et al. The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43). Neurology 1997;48:741-745